NUWE Stock Analysis: Buy, Sell, or Hold?
NUWE - Nuwellis, Inc. Common Stock
$0.17
-0.26 (-61.21%)
▼
5d:
-78.39%
30d:
-84.66%
90d:
-88.31%
WAIT
LOW Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When NUWE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: NUWE is down 78.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: NUWE is down 78.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: NUWE is currently trading at $0.17, which is considered oversold relative to its 30-day fair value range of $0.69 to $1.17.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 61.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+6478.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUWE is in a downtrend. The price is currently testing key support at $0.48. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 61.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $11.00 (+6478.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.69 -
$1.17
Company Quality Score
44/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
72.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BEARISH: Downward momentum (-61.2%)
- BULLISH: Trading 6478.9% below Wall St target ($11.00)
- WARNING: Recommendation downgraded due to -78.4% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$0.69 -
$1.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.48
Resistance Level
$1.05
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.27
Wall Street Target
$11.00
(+6478.9%)
Revenue Growth (YoY)
26.2%
Earnings Growth (YoY)
-99.2%
Profit Margin
-214.9%
Share & Embed Analysis
Last updated: June 06, 2026 7:54 AM ET
Data refreshes hourly during market hours. Next update: 8:54 AM
Data refreshes hourly during market hours. Next update: 8:54 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUWE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$82 | 64 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$389 | 55 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$107 | 63 BUY |
|
PODD
Insulet Corporation |
STRONG BUY
23 analysts |
$247 | 59 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$97 | 56 HOLD |
